Enesi
Pharma (“Enesi”), an innovative biotechnology company developing
next-generation vaccination products targeting infectious diseases and emergent
threat pathogens enabled by its ImplaVax technologies, is delighted to report
positive top-line results from a new study evaluating the immune responses
generated by an ImplaVax-enabled unit solid-dose formulation of classical
swine fever (CSF) vaccine.
The results
showed that a novel solid-dose ImplaVax formulation of a recombinant E2
antigen CSF virus vaccine delivered subcutaneously using the ImplaVax needle-free injection device generated a stronger immune response than standard
liquid CSF vaccine formulations, particularly in terms of CSF virus-specific
T-cell responses.
CSF is a
significant animal health issue that causes a highly contagious haemorrhagic
fever in pigs, which is deadly in its acute form. Due to its severe economic
impact, CSF is notifiable to the world organisation for animal health (OIE).
The disease is endemic in parts of Asia with significant adverse impacts on
animal health, food security and the pig industry. Despite extensive efforts in
CSF virus research, diagnostics and eradication, the virus continues to persist
and re-emerge, posing a threat for food supply in affected regions (Ganges et al., 2020).
More details of the study and
its results will be presented in an upcoming publication.
David Hipkiss, Enesi Pharma
CEO, commented:
“We are delighted to report
positive top-line results from this successful study. These new results with a
solid-dose recombinant protein subunit vaccine reinforce the strong potential
of ImplaVax in the growing global animal health market, and build on the
recent positive results in Porcine Reproductive and Respiratory Syndrome (PRSS)
with a solid-dose live attenuated virus vaccine undertaken with The Pirbright
Institute.
“In particular, these
results highlight the applicability of the ImplaVax platform across multiple
proven vaccine formats and into human health given the relative similarity of
skin models and immune responses between pigs and humans. This gives us
confidence in the potential of our ImplaVax-enabled solid-dose vaccine formats
to generate positive results and demonstrate the myriad associated benefits in
our many other partnerships and applications targeting infectious diseases in
humans.”
